Kisaprida: Perbedaan antara revisi

Di banyak negara, obat telah ditarik atau memiliki indikasi yang terbatas karena laporan dari efek samping [[sindrom perpanjangan interval QT]], yang dapat menyebabkan [[aritmia]]. [[Food and Drug Administration]] (FDA) Amerika Serikat mengeluarkan surat peringatan kepada dokter,<ref name="urlFDA UPDATES WARNINGS FOR CISAPRIDE">{{cite web |url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175000.htm |title=Propulsid (cisapride) Safety Information |work= |accessdate=2011-07-14}}</ref> dan cisaprid telah sukarela dihapus dari pasar AS pada 14 Juli 2000. Penggunaannya di Eropa juga terbatas. Obat dilarang di India dan di Filipina pada tahun 2011.<ref name=GERD2010>{{cite journal|last=Maclennan|first=S|author2=Augood, C |author3=Cash-Gibson, L |author4=Logan, S |author5= Gilbert, RE |title=Cisapride treatment for gastro-oesophageal reflux in children.|journal=The Cochrane database of systematic reviews|date=Apr 14, 2010|issue=4|pages=CD002300|pmid=20393933 |doi=10.1002/14651858.CD002300.pub2}}</ref> It was banned in India and in the Philippines in 2011.<ref name=ban>{{cite web|url=http://cdsco.nic.in/html/drugsbanned.html|title=Drugs banned in India|publisher=Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India|accessdate=2013-09-17|archive-date=2015-02-21|archive-url=https://web.archive.org/web/20150221053621/http://cdsco.nic.in/html/drugsbanned.html|dead-url=yes}}</ref>

[[Kategori:SenyawaJanssen fluorPharmaceutica]]

[[Kategori:SenyawaAgonis organikreseptor serotonin]]